In refractory multiple myeloma, for example, longitudinal scRNA-seq identified peptidylprolyl isomerase A (PPIA) as a transcriptomic signature of resistance, but its functional validation as a therapeutic target requires confirmation at the protein level [84]. This evidence concerns the gene PPIA and AL amyloidosis.